Browsing by Author "Arslan, H."

Now showing 1 - 3 of 3

BLOOD STREAM INFECTIONS DUE TO EXTREMELY DRUG-RESISTANT GRAM NEGATIVE PATHOGENS IN SOLID ORGAN TRANSPLANT RECIPIENTS: EPIDEMIOLOGY, RISK FACTORS AND MORTALITY
(2019) Erol, C.; Melike, H. Demirkaya; Soy, E. Ayvazoglu; Arslan, H.; Haberal, M.
Mucormycosis in Haematological Malignancy Patients
(2017) Kursun, E.; Turunc, T.; Demiroglu, Z.; Solmaz, S.; Arslan, H.; 0000-0002-5708-7915; 0000-0001-7956-7306; ABG-7034-2021; GVT-0626-2022
Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia
(2020) Arslan, H.; 31891235
Treatment of carbapenemase-producing Enterobacterales bloodstream infections in solid organ transplant recipients is challenging. The objective of this study was to develop a specific score to predict mortality in solid organ transplant recipients with carbapenemase-producing Enterobacterales bloodstream infections. A multinational, retrospective (2004-2016) cohort study (INCREMENT-SOT, ClinicalTrials.gov NCT02852902) was performed. The main outcome variable was 30-day all-cause mortality. The INCREMENT-SOT-CPE score was developed using logistic regression. The global cohort included 216 patients. The final logistic regression model included the following variables: INCREMENT-CPE mortality score >= 8 (8 points), no source control (3 points), inappropriate empirical therapy (2 points), cytomegalovirus disease (7 points), lymphopenia (4 points), and the interaction between INCREMENT-CPE score >= 8 and CMV disease (minus 7 points). This score showed an area under the receiver operating characteristic curve of 0.82 (95% confidence interval [CI] 0.76-0.88) and classified patients into 3 strata: 0-7 (low mortality), 8-11 (high mortality), and 12-17 (very-high mortality). We performed a stratified analysis of the effect of monotherapy vs combination therapy among 165 patients who received appropriate therapy. Monotherapy was associated with higher mortality only in the very-high (adjusted hazard ratio [HR] 2.82, 95% CI 1.13-7.06, P = .03) and high (HR 9.93, 95% CI 2.08-47.40, P = .004) mortality risk strata. A score-based algorithm is provided for therapy guidance.